Lemelson Doubles Short Position In Ligand Pharmaceuticals, Says It's Created 'Pyramid Scheme Of Shell Companies'

Rev. Emmanuel Lemelson was recently a guest on #PreMarket Prep, a daily trading idea radio show hosted by Joel Elconin and Dennis Dick. 

Shares of Ligand Pharmaceuticals Inc. LGND hit new 52-week highs of $94.94 on Friday after the company updated the impact from the Viking Therapeutics Inc VKTX initial public offering.

Ligand said that it sees $28.2 million of non-operating income during the second quarter related to its "gain on deconsolidation" from the Viking IPO of which the firm showed a nearly 50 percent ownership stake. The company also adjusted its full year 2015 earnings per share guidance from $2.14 to $2.18 to a new range $3.45 to $3.50, which accounts for the IPO.

Lemelson Short

One hedge fund manager took the opportunity to add to his short position in Ligand on the news.

Reverand Emmanuel Lemelson of Lemelson Capital Management discussed why he doubled his short position on Thursday during Friday's Benzinga #Premarket Pep show.

In Lemelson's words, Ligand has created a "pyramid scheme of shell companies" by IPO'ing Viking that has "almost no prospect" of future revenue and earnings with no assets. In the future, he said, Ligand will be used as a case study in to the "excesses of the stock market."

He continued that Viking is merely a "tenant in their building" with "a few people renting space," while underwriters are promoting the issue "like it's going out of fashion."

Lemelson argued that Ligand is using its ownership stake to boost its balance sheet with the profits from the IPO being recorded as earnings. Ligand won't record any losses in its P&L from Viking even though the company "is guaranteed" to show losses in the future, he added.

"That's extraordinary financial engineering," the hedge fund manager argued. "That really makes the Greece financial apparatus look like saints."

In his opinion, Lemelson concluded that the company isn't "building a real product or business" and is merely a company with 18 employees and a $2 billion market capitalization.

"That's the kind of thing you want to short. It's just not sustainable."

Lemelson's commentary on Ligand begins at the 1:37:20 mark below.

Posted In: #PreMarketPrepDennis DickEmmanual LemelsonJoel ElconinLemelsn Capital ManagementPyramid SchemeAnalyst ColorBiotechShort IdeasExclusivesTrading IdeasInterviewGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.